BACKGROUND: Stress can increase impulsivity and has a negative impact on psychiatric outcome. Norepinephrine is heavily implicated in responses to stress, and the alpha(2) antagonist yohimbine is used clinically to study this aspect of the stress response. Yohimbine induces mild anxiety and increases impulsivity in healthy volunteers but has more detrimental effects in some psychiatric populations, triggering mania in bipolar patients and drug craving in substance-dependent individuals. Understanding the mechanism by which yohimbine affects brain function could provide insight into the heightened reaction to stress in these patients. METHODS: Yohimbine's effects were assessed in rats using the five-choice serial reaction time test of attention and impulse control. We then examined whether yohimbine altered activity of cyclic adenosine monophosphate response element binding (CREB) protein-a transcription factor implicated in the stress response-in brain areas that regulate impulsivity. The behavioral consequences of any changes in CREB activity were subsequently assessed using viral-mediated gene transfer to regionally overexpress CREB or the dominant negative antagonist mCREB. RESULTS: Yohimbine increased impulsive responding in rats and selectively increased CREB phosphorylation within the orbitofrontal cortex but not medial prefrontal cortex or nucleus accumbens. Overexpressing mCREB within the orbitofrontal cortex blocked yohimbine's effects on impulsivity, whereas overexpressing CREB in this region increased impulsive responding and potentiated the proimpulsive actions of yohimbine. DISCUSSION: These data suggest a novel molecular mechanism contributing to impulsivity that may be sensitive to stress. Such findings may improve our understanding of the neurobiological pathways linking the response to stress and impulsivity in both healthy and psychiatric populations. Copyright 2010 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.
BACKGROUND:Stress can increase impulsivity and has a negative impact on psychiatric outcome. Norepinephrine is heavily implicated in responses to stress, and the alpha(2) antagonist yohimbine is used clinically to study this aspect of the stress response. Yohimbine induces mild anxiety and increases impulsivity in healthy volunteers but has more detrimental effects in some psychiatric populations, triggering mania in bipolarpatients and drug craving in substance-dependent individuals. Understanding the mechanism by which yohimbine affects brain function could provide insight into the heightened reaction to stress in these patients. METHODS:Yohimbine's effects were assessed in rats using the five-choice serial reaction time test of attention and impulse control. We then examined whether yohimbine altered activity of cyclic adenosine monophosphate response element binding (CREB) protein-a transcription factor implicated in the stress response-in brain areas that regulate impulsivity. The behavioral consequences of any changes in CREB activity were subsequently assessed using viral-mediated gene transfer to regionally overexpress CREB or the dominant negative antagonist mCREB. RESULTS:Yohimbine increased impulsive responding in rats and selectively increased CREB phosphorylation within the orbitofrontal cortex but not medial prefrontal cortex or nucleus accumbens. Overexpressing mCREB within the orbitofrontal cortex blocked yohimbine's effects on impulsivity, whereas overexpressing CREB in this region increased impulsive responding and potentiated the proimpulsive actions of yohimbine. DISCUSSION: These data suggest a novel molecular mechanism contributing to impulsivity that may be sensitive to stress. Such findings may improve our understanding of the neurobiological pathways linking the response to stress and impulsivity in both healthy and psychiatric populations. Copyright 2010 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.
Authors: Ming-Hu Han; Carlos A Bolaños; Thomas A Green; Valerie G Olson; Rachael L Neve; Rong-Jian Liu; George K Aghajanian; Eric J Nestler Journal: J Neurosci Date: 2006-04-26 Impact factor: 6.167
Authors: Catharine A Winstanley; Quincey LaPlant; David E H Theobald; Thomas A Green; Ryan K Bachtell; Linda I Perrotti; Ralph J DiLeone; Scott J Russo; William J Garth; David W Self; Eric J Nestler Journal: J Neurosci Date: 2007-09-26 Impact factor: 6.167
Authors: Elena H Chartoff; Maria Papadopoulou; Matt L MacDonald; Aram Parsegian; David Potter; Christine Konradi; William A Carlezon Journal: Mol Pharmacol Date: 2008-12-23 Impact factor: 4.436
Authors: Yan Dong; Thomas Green; Daniel Saal; Helene Marie; Rachael Neve; Eric J Nestler; Robert C Malenka Journal: Nat Neurosci Date: 2006-03-05 Impact factor: 24.884
Authors: Erin B Larson; Danielle L Graham; Rose R Arzaga; Nicole Buzin; Joseph Webb; Thomas A Green; Caroline E Bass; Rachael L Neve; Ernest F Terwilliger; Eric J Nestler; David W Self Journal: J Neurosci Date: 2011-11-09 Impact factor: 6.167
Authors: Alison K Berger; Thomas Green; Steven J Siegel; Eric J Nestler; Ronald P Hammer Journal: Biol Psychiatry Date: 2010-10-30 Impact factor: 13.382
Authors: Jim McBurney-Lin; Yina Sun; Lucas S Tortorelli; Quynh Anh T Nguyen; Sachiko Haga-Yamanaka; Hongdian Yang Journal: Neuropharmacology Date: 2020-05-21 Impact factor: 5.250